

### JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office: T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA) Fax: 0091-11-26498341, 26494708. Phone: 0091-11-26494519-24

CIN: L74899DL1978PLC009181

JPL/Stock-Corr-2013	August 12th, 2016			
The Manager Listing Agreement The National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051	The Manager Listing Agreement The Bombay Stock Exchange Ltd. Pherojbhoy Jeejeebhoy Tower Dalal Street, Mumbai - 400 001.			
CM Quote : JAGSNPHARM	Scrip Code : 507789			
OUT-COME OF THE MEETIN JAGSONPAL PHARMACEUTI	NG OF BOARD OF DIRECTORS OF ICALS LIMITED HELD ON 12.08.2016			

#### Sir,

- Performance of the 1st Quarter and three months ended 30.06.2016 (Un-audited) was placed before the Board having reviewed by the Audit Committee. The issue was discussed.
- Approval of Quarterly performance and three months ended 30.06.2016 was approved by the Board of Directors and resolution in this regard was passed with an authority to Managing Director to publish in newspapers and send same to National Stock Exchange of India Limited (NSE) & Bombay Stock Exchange Limited (BSE).
- Auditors Limited Review statement is enclosed.
- Cost Audit Report was also approved and taken on record by the Board.
- Other routine matters were discussed by Board and taken care.
- Any another matter with the permission. Meeting concluded with vote of thanks,
- The meetings commence at 12.00 noon and concluded at 2.00 p.m.

Thanking you,

Yours faithfully,

For JAGSONPAL PHARMACEUTICALS LYM

R K KAPOOR COMPLIANCE OFFICER CUM COMPANY SECRETARY

Factory: 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone: 0091-95129-2275952, 2275953 Factory: Plot No. 14, 15, 16, 55, 56, 57, Sector-5, IIE, Pant Nagar, Rudrapur (U.S. Nagar) - 263153 Uttara Khand

New Delhi

CIN No. L74899DLI978PLC( 1181



# JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office: T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA) Fax: 0091-11-26498341, 26494708, Phone: 0091-11-26494519-24

# CIN No:- L74899DL1978PLC009181 JAGSONPAL PHARMACEUTICALS LIMITED Unaudited Financial Results for the Quarter ended 30.06.2016

	Oraquited Financial Results for the Quarter ended 30.00.2010						
	PART-I				Rs. in lacs		
	Particulars	3 months ended 30.06.2016 Unaudited	3 months ended 31.03.2016 Audited	3 months ended 30.06.2015 Unaudited	12 Months ended 31.03.2016 Audited		
1	Income from operations						
а	Net sales/Income from Operations (Net of	4011.02	3892.01	3698.85	14348.79		
6	excise duty)	40.45	00.00		50.00		
b	Other Operating Income	13.15	28.32	2000.05	59.26		
	Total Income from operations (net)	4024.17	3920.33	3698.85	14408.05		
2	Expenses						
a	Cost of materials consumed	1673.9	907.44	1310.02	5627.89		
b	Purchases of stock-in-trade	374.99	164.28	117.40	906.68		
C.	Changes in inventories of finished goods, work	-422.43	356.89	507.09	-622.24		
d.	Employee benefits expenses	1116.11	1070.91	823.60	3783.71		
e.	Depreciation and amortisation expense	70.43	92.92	69.14	309.36		
f.	Other expenses	1036.16	927.6	687.92	3471.80		
	Total expenses	3849.16	3520.04	3515.17	13477.20		
3	Profit from Operations before Other Income,						
	Finance Cost and Exceptional items (1-2)	175.01	400.29	183.68	930.85		
4	Other Income	0.03	0.07	2.90	6.38		
5	Profit from ordinary activities before finance cost	175.04	400.36	186.58	937.23		
	and Exceptional items (3+4)						
6	Finance Cost	94.87	164.48	123.33	529.71		
7	Profit from ordinary activities after finance cost	80.17	235.88	63.25	407.52		
	but before Exceptional Items (5-6)						
8	Exceptional Items						
9	Profit(+)/Loss(-) from Ordinary Activities before	80.17	235.88	63.25	407.52		
	tax (7+8)						
10	Tax expense	16.03	35.77	16.70	82.10		
11	Net Profit/Loss(-) from Ordinary Activities after	64.14	200.11	46.55	325.42		
	tax (9-10)						
12	Extraordinary Items (net of tax expense Rs. lacs)						
13	Net Profit(+)/Loss(-) for the period(11-12)	64.14	200,11	46.55	325.42		
14	Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90		
15	Reserves excluding Revaluation reserves as per						
	Balance sheet of pr. Accounting yr				7742.63		
16	Earnings Per Share (before extraordinary items)						
a.	Basic (Rs.)	0.24	0.76	0.18	1.24		
	Diluted (Rs.)	0.24	0.76	0.18	1.24		
Note	Notes						

- The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 12, 2016.
- 2) The Company operates in one reportable business segment i.e. 'Pharmaceuticals'.
- Figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period
- 4) The above results are available on website of the company www.jagsonpal.com.

By Order of the Board

For Jagsonpal Pharmaceuticals kimited

Place: New Delhi Date: 12.08.2016 To Mew Delhi Ling

Rajpal Singh Kochhar Managing Director DIN No 00059492

Factory: 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone: 0091-95129-2275952, 2275953 Factory: Plot No. 14, 15, 16, 55, 56, 57, Sector-5, IIE, Pant Nagar, Rudrapur (U.S. Nagar) - 263153 Uttara Khand

## P.P. THUKRAL & CO.

CHARTERED ACCOUNTANTS

42, Ground Floor, World Trade Centre, Babar Road, New Delhi - 110 001

Ph. (O): 23413486

E-mail: sureshsethi62@yahoo.com

The Board of Director
Jagsonpal Pharmaceuticals Limited
T-210 J, Shahpur Jat
New Delhi - 110049

### SUBJECT: LIMITED REVIEW REPORT FOR JAGSONPAL PHARMACEUTICALS LIMITED

We have reviewed the unaudited financial results of Jagsonpal Pharmaceuticals Limited (the "Company") the Quarter ended 30.06.2016 which are included in the accompanying "Statement of Standalone Unaudited Financial Results for the Quarter ended 30th, June 2016" (the "statement"). The statement has been prepared by the Company pursuant to Regulation 33 of the SEBI, 2015 (Listing Obligations and Disclosure Requirements) Regulations 2015 (the Listing Regulations 2015) which has been initialed by us for identification purposes.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, engagements to Review of Interim Financial Information Performed by Independednt Auditor of the entity" by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards specified under Section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) rule 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed including the manner in which it is to be disclosed, or that it contains any material misstatement.

A NEW DELHI SO A NEW DELANDER

for P. P. THUKRAL & CO., Chartered Accountants

> SURESH SETHI PARTNER F.R. No. 000632N Membership No. 89318

Place: New Delhi Date: 12.08.2016